Pilot Study to Evaluate Compliance and Tolerability of Cranberry Capsules in Pregnancy for the Prevention of Asymptomatic XXXX .

@entity1 @entity344 @entity793 @entity2885 @entity2335
OBJECTIVES: To evaluate the compliance with and tolerability of daily cranberry capsule ingestion for asymptomatic @entity793 (ASB) prevention in pregnancy. DESIGN: A total of 49 pregnant @entity1 from two sites were randomly assigned to cranberry or matching placebo, two doses daily, at gestational ages less than 16 weeks. @entity1 were followed monthly for urinary tract infection until delivery. Up to seven monthly visits were scheduled for each @entity1 . Delivery data were evaluated. RESULTS: Of 38 evaluable @entity1 , the mean compliance rate over the study period was 82% (range, 20%-100%). This compliance rate and the 74% of @entity1 achieving good (>= 75%) compliance were similar between those who received cranberry capsules and placebo. Compliance evaluation revealed that most @entity1 stopped capsule consumption after 34-38 weeks of participation. Multivariate logistic regression and longitudinal analysis showed a significant interaction time effect with cranberry treatment. However, cranberry consumption was not a significant predictor of @entity344 or study withdrawal. Although 30% of @entity1 withdrew for various reasons, only 1 withdrew because of intolerance to the cranberry capsules. Loss to follow-up was mostly due to provider change (9 of 49 [18%]) and therapy disinterest (4 of 49 [8%]). Seven cases of ASB occurred in 5 @entity1 : 2 of 24 (8%) in the cranberry group and 3 of 25 (12%) in the placebo group. No cases of @entity2335 or @entity2885 were observed. CONCLUSION: One third of pregnant @entity1 could not complete the study protocol for various reasons. Compliance with and tolerability of cranberry capsule ingestion appear good; these capsules provide a potentially effective means to prevent ASB in pregnancy. Further studies with large samples are necessary to confirm the findings.
